pegs korea 2015 preliminary agenda
TRANSCRIPT
PRELIMINARY AGENDA ANNOUNCEMENTPEGS is Cambridge Healthtech institute (CHI)’s flagship biologics meeting, and is widely considered the industry’s leading event on protein and antibody engineering. Its successful accolades include an annual attendance of over 1800 participants at the PEGS Summit in Boston; a record attendance of over 500 attendees at PEGS Europe this year; a successful launch of PEGS China in 2014, and now, the announcement of the first PEGS Korea to be launched in September 2015.
The 3-day Inaugural PEGS Korea will bring together an international faculty consisting of scientists, engineers and executives from all over the world to share their expertise and experiences in protein and antibody engineering, particularly in developing next-generation therapeutics including ADCs, bispecifics, and immunomodulating antibodies.
SEPTEMBER 1-3, 2015 | JW MARRIOTT SEOUL | SEOUL, KOREA
REGISTER BY MAY 1 FOR EARLY BIRD SAVINGS UP TO $600!
PLEASE SEE REVERSE SIDE FOR PRELIMINARY AGENDA
For exhibit and sponsorship information, please contact:(Companies A-K)Jason GerardiManager, Business DevelopmentCambridge Healthtech InstitutePhone: (+1) 781-972-5452Email: [email protected]
(Companies L-Z)Carol DinersteinManager, Business DevelopmentCambridge Healthtech InstitutePhone: (+1) 781-972-5471Email: [email protected]
Corporate Sponsor
PEGSummitKOREA.com
KEYNOTE SPEAKERSAndrew Bradbury At the Crossroads: Getting to Reproducible Research AntibodiesAndrew Bradbury , M.B.B.S., Ph.D., Biosciences Division, Los Alamos National Laboratory
Greg Adams Developing Antibodies against Difficult Targets Using Computational ApproachesGregory P. Adams, Ph.D., Director of Biological Research and Therapeutics, Fox Chase Cancer Center
TARGET DISCOVERY & VALIDATIONIdentification of New Therapeutic Targets of Hepatocellular CarcinomaGwanghee Lee, Ph.D., Cancer Project Leader, Therapeutic Strategic Unit, Asia Pacific R&D, Sanofi
BIOLOGICS TARGETING INTRACELLULAR PROTEINS
Delivering Antibodies into the Cell: Towards a New Therapeutic Paradigm?Stefan Duebel, Ph.D., Professor and Managing Director, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universitat Braunschweig, Germany
Cytosol-Penetrating IgG Antibody and Its Application for Targeting Cytosolic ProteinsYong-Sung Kim, Ph.D., Professor, Department of Molecular Science & Technology, Ajou University, Korea
ENGINEERING OF NOVEL FORMATS AND NEXT GENERATION PROTEINS & IMMUNOTHERAPIES
Beyond Antibodies: Rational Design of Oncology Biotherapeutics with Improved ActivitiesAlexey Lugovskoy, Ph.D., Vice President, Therapeutics, Merrimack Pharmaceuticals
Engineering Aglycosylated Full-Length IgG Antibodies for Next Generation ImmunotherapeuticsSang Taek Jung, Ph.D., Professor, Department of Bio and Nano Chemistry, Kookmin University
Single-Step Ultra-Humanization, Stabilization and Essential Paratope Sampling of Murine, Avian and Leporid IgGsWilliam (Jonny) Finlay, Ph.D., Director, Protein Discovery & Optimization, Global Biotherapeutics Technologies, Pfizer Ireland
Developing Antibodies to HLA-Peptide Molecules for Next Generation TherapeuticsJon Weidanz, Ph.D., Professor, Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center
CANCER IMMUNOTHERAPIESEngineering Multiple Immune Checkpoint Blockades for Cancer TherapyCheng-I Wang, Ph.D., Principal Investigator, Therapeutic Antibody Engineering, Singapore Immunology Network
BIOCONJUGATESImaging Intracellular Activity of Antibody-Drug ConjugatesByoung-Chul Lee, Ph.D., Scientist, Protein Chemistry, Genentech, Inc.
NexMabTM, a Site-Specific Antibody-Drug Conjugation Method by Utilizing Ligand-Protected Cysteine-Containing Motifs, and Its Application to Herceptin-Drug ConjugateSoon Jae Park, Ph.D., CEO, Alteogen, Inc.
BISPECIFIC ANTIBODIESClinical Development of Tanibirumab and Next Generation Bispecific AntibodiesJin-San Yoo, Ph.D., CEO, President & Founder, PharmAbcine
A Novel Bispecific Antibody Targeting VEGF and DLL4 Inhibits Tumor ProgressionWeon-Kyoo You, Principal Research Scientist, Biologics Unit, Hanwha Chemical
NEXT GENERATION ANTIBODIESAction Mechanism-Guided Competitiveness Design of GC1118, a Novel Anti-EGFR AntibodyJonghwa Won, Ph.D., Senior Research Director, Oncology Team, Mogam Biotechnology Institute
COMBINATION CANCER THERAPIESCombination of Novel HER2 Targeting Antibody 1A12 with Trastuzumab Shows Synergistic Antitumor Activity in HER2 Positive Gastric CancerKyu-Tae Kim, Ph.D., Director, ADDs, AbClon Inc.
THERAPEUTIC ENZYMESMolecular Engineering to Improve the Therapeutic Potential of the Enzyme L-Asparaginase Used for the Treatment of LeukemiaManfred Konrad, Ph.D., Professor, Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry
Protein and Antibody Engineering
Next Generation Antibody Therapeutics
SEPTEMBER 1-2 SEPTEMBER 2-3
For inquiries on the program agenda and speaking opportunities, please contact:
Mimi LangleySenior Conference DirectorCambridge Healthtech InstitutePhone: (+1) 816-471-0701Email: [email protected]